Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis
Patrick Vermersch, Luís Brieva, Robert J. Fox, Friedemann Paul et autres
BACKGROUND AND OBJECTIVES: Masitinib is a selective tyrosine kinase inhibitor, targeting innate immune cells (mast cells and microglia) that are involved in the pathophysiology of progressive multiple sclerosis (MS). Study AB07002 assessed oral masitinib in patients with progressive MS who were progressing …
fr, es, pl, de (code pays fourni par la source)
71 citations
Neurology Neuroimmunology & Neuroinflammation